New triple-drug combo aims to extend life in advanced liver cancer
Disease control
Not yet recruiting
This phase 3 trial tests whether adding TPST-1120 to standard immunotherapy and anti-angiogenesis drugs helps people with advanced liver cancer live longer. About 740 adults whose cancer cannot be surgically removed or has spread will be randomly assigned to receive either the tr…
Phase: PHASE3 • Sponsor: Tempest Therapeutics • Aim: Disease control
Last updated May 17, 2026 13:02 UTC